New Alzheimer’s Treatment Shows Promise in Recent Clinical Trials
Anavex Life Sciences has announced encouraging results from their recent phase 2b/3 clinical trial, bringing new hope to those affected by early Alzheimer’s disease. The investigational agent, blarcamesine (ANAVEX®2-73), demonstrated significant efficacy in reducing amyloid-ß biomarkers and slowing neurodegeneration among study participants. The multicenter, randomized, double-blind, placebo-controlled trial included 508 participants diagnosed with early symptomatic […]